Cerenis Appoints John F. Paolini as Chief Medical Officer
Cerenis Therapeutics announced the appointment of John F. Paolini, MD, PhD, FACC as Chief Medical Officer.
Dr Paolini will be responsible for the strategic planning and execution of the clinical trials for Cerenis’ portfolio of novel cardiovascular therapies and, most importantly, Cerenis’ lead product,CER-001, a pre-beta HDL mimetic currently in Phase II clinical trials for patients with acute coronary syndrome.
Dr. Paolini has more than 15 years of clinical and research experience in cardiovascular disease, the last decade being focused on clinical development in the pharmaceutical industry: notably, at Merck & Co., Inc he led development programs of novel therapies for dislipidemic patients (Tredaptive® the Nicotinic acid/laropripant combination and Vytorin®/Inegy® the Ezetimibe/Simvastatin combination tablet), and at Bayer Healthcare Pharmaceuticals, he led the clinical development program for a novel anticoagulant agent for patients with atrial fibrillation (Xarelto,® the direct factor Xa inhibitor, rivaroxaban). He is board certified in Cardiovascular Disease, a Fellow of the American College of Cardiology and has served as a Clinical Associate in Cardiovascular Medicine at the Hospital of the University of Pennsylvania. Dr. Paolini has been involved in the publication of over fifty abstracts and scientific papers.
Other news from the department people
